BAY 2586116
Alternative Names: BAY-2586116Latest Information Update: 28 Jun 2024
At a glance
- Originator Bayer
- Class Sleep disorder therapies
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Sleep apnoea syndrome
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Sleep-apnoea-syndrome(In volunteers) in Japan (Intranasal, Spray)
- 20 Dec 2022 Bayer completes a phase I trial for Sleep apnoea syndrome (In adults, In the elderly) in Australia (Intranasal, Spray) (NCT05527457)
- 01 Sep 2022 Bayer initiates enrolment in a phase I trial for Sleep apnoea syndrome (In adults, In the elderly) in Australia (Intranasal, Spray) (NCT05527457)